Mometasone Furoate
| Evidence Level: L5 | Predicted Indications: 55 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Mometasone Furoate |
| DrugBank ID | DB14512 |
| Brand Names (EU) | Atectura Breezhaler, Mometasone furoate, Zimbus Breezhaler |
| Evidence Level | L5 |
| Predicted Indications | 55 |
| Top Prediction Score | 99.72% |
Approved Indication (EMA)
Bemrist Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | atopic eczema | 99.72% | DL |
| 2 | dermatitis, atopic | 99.33% | DL |
| 3 | 2-hydroxyethyl methacrylate sensitization | 98.62% | DL |
| 4 | seborrheic dermatitis | 98.10% | DL |
| 5 | polyp of vocal cord | 97.67% | DL |
| 6 | polyp of middle ear | 97.65% | DL |
| 7 | polyp of frontal sinus | 97.56% | DL |
| 8 | polyp of external auditory canal | 97.55% | DL |
| 9 | fibroepithelial polyp | 97.55% | DL |
| 10 | polyp of vulva | 97.54% | DL |
| 11 | polyp of ureter | 97.53% | DL |
| 12 | epulis | 97.53% | DL |
| 13 | neoplastic polyp | 97.51% | DL |
| 14 | uterine polyp | 97.50% | DL |
| 15 | primary cutaneous T-cell non-Hodgkin lymphoma | 97.30% | DL |
| 16 | alopecia mucinosa | 97.21% | DL |
| 17 | alopecia areata | 97.09% | DL |
| 18 | telogen effluvium | 97.05% | DL |
| 19 | Quinquaud’s folliculitis decalvans | 96.70% | DL |
| 20 | seborrheic keratosis | 96.63% | DL |
Showing top 20 of 55 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.